Celldex Reports Positive Phase 2 Barzolvolimab Data for Urticaria Treatment

Key Facts

1Celldex presented additional positive Phase 2 data for barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU).

2Data showed sustained off-treatment efficacy, suggesting potential disease modification in CSU patients.

3The drug targets mast cells, which are considered the root cause of these skin conditions.

Celldex Therapeutics (NASDAQ: CLDX) has released additional positive data from its Phase 2 clinical trials for barzolvolimab, a treatment for chronic spontaneous urticaria (CSU) and cold urticaria (ColdU). The findings, presented at the AAAAI 2026 Annual Meeting, highlight the drug's potential as a first-in-class therapy targeting mast cells, the underlying cause of these conditions. Notably, the data demonstrated sustained efficacy even after treatment was discontinued, suggesting a potential for disease modification in patients. Investors are reacting positively to these clinical milestones, as barzolvolimab continues to show a best-in-disease profile with significant quality-of-life improvements. The successful results reinforce the company's leading position in the biotech sector's dermatology pipeline. This development is expected to serve as a significant catalyst for the company's stock performance as it moves toward further regulatory milestones.